Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Am Pharm Assoc (Wash). 2002 Sep-Oct;42(5):753-66; quiz 766-7.

Providing pharmaceutical care to the multiple sclerosis patient.

Author information

  • 1College of Pharmacy, University of Kentucky, Lexington 40536-0082, USA.

Abstract

OBJECTIVE:

To review the pathophysiology, symptoms, and treatment of multiple sclerosis (MS).

DATA SOURCES:

Recently published clinical literature identified through review of articles abstracted at MEDLINE. Search terms included multiple sclerosis, interferon beta, glatiramer acetate, mitoxantrone, treatment, symptoms, steroids, etiology, and neutralizing antibodies.

STUDY SELECTION:

Performed manually by the authors.

DATA EXTRACTION:

Performed manually by the authors.

DATA SYNTHESIS:

MS is a chronic disease of the central nervous system that most often strikes patients in their early 30s. Noticeable geographic, ethnic, racial, and sex differences in incidence remain unexplained. Diagnosis relies heavily on the presence of neurologic signs and symptoms, and magnetic resonance imaging of the brain is increasingly useful. Treatment with steroids, interferon beta-1b (Betaseron-Berlex) and interferon beta-1a (Avonex-Biogen; Rebif-Serono), and glatiramer acetate (Copaxone-Teva) can produce periods of remission in patients with MS. Management of adverse medication effects and disease-related symptoms of fatigue, pain, and bladder dysfunction is important in these patients.

CONCLUSION:

MS is currently incurable but largely treatable. Research has produced promising new medications, and investigational therapies hold promise for better treatment of this debilitating condition.

PMID:
12269710
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk